Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
AB103
100%
Academic Medical Centers
16%
Adverse Events
16%
Antibiotic Therapy
16%
Bacterial Toxins
16%
Baseline Characteristics
16%
Baseline Scores
16%
CD28
16%
Change from Baseline
16%
Change of Measure
16%
Clinically Significant
16%
Cytokine Levels
33%
Debridement
33%
Double-blinded Study
16%
Drug Adverse Events
16%
High Dose
50%
High Morbidity
16%
High Mortality
16%
Inflammation
16%
Inflammatory Response
16%
Intensive Care Unit
33%
Intent-to-treat Analysis
33%
Intravenous Dose
16%
Low-dose Treatment
16%
Lymphocyte Receptors
16%
Morbidity Rate
16%
Mortality Rate
16%
Necrotizing Soft Tissue Infection
100%
New Agents
16%
Organ Failure
16%
Peptidomimetics
16%
Placebo
16%
Placebo Groups
50%
Prospective Randomized Trial
16%
Randomized Clinical Trial
100%
Randomized Placebo-controlled Trial
16%
Sequential Organ Failure Assessment
33%
Surgical Debridement
16%
T Cells
16%
Treatment Group
33%
United States
16%
Ventilator-free Days
33%
Medicine and Dentistry
Adverse Event
33%
Antibiotic Therapy
16%
Arm
33%
Bacterial Toxin
16%
Cytokine
33%
Debridement
50%
Diseases
16%
Drug Megadose
50%
Intensive Care Unit
33%
Intention-to-Treat Analysis
33%
Intravenous Drug Administration
16%
Low Drug Dose
50%
Mortality Rate
16%
Placebo
83%
Randomized Clinical Trials
100%
Serositis
16%
SOFA Score
33%
Soft Tissue Infection
100%
T Lymphocyte Receptor
16%
Treatment Group
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Antibiotic Therapy
16%
Bacterial Toxin
16%
Cytokine
33%
Diseases
16%
Inflammation
33%
Mortality Rate
16%
Organ Dysfunction Score
33%
Placebo
83%
Randomized Clinical Trial
100%
Soft Tissue Infection
100%
T Lymphocyte Receptor
16%
Treatment Group
33%